Glaukos Corp (NYSE: GKOS) has recently received a number of price target changes and ratings updates:

  • 9/12/2017 – Glaukos Corp was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/1/2017 – Glaukos Corp was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 9/1/2017 – Glaukos Corp had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $54.00 price target on the stock.
  • 8/26/2017 – Glaukos Corp was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/16/2017 – Glaukos Corp was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/7/2017 – Glaukos Corp was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 8/5/2017 – Glaukos Corp was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Glaukos Corp was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $41.00 price target on the stock. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 8/3/2017 – Glaukos Corp had its price target lowered by analysts at Roth Capital from $60.00 to $54.00. They now have a “buy” rating on the stock.
  • 8/3/2017 – Glaukos Corp had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $56.00 price target on the stock.
  • 7/24/2017 – Glaukos Corp was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 7/21/2017 – Glaukos Corp was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $46.00 price target on the stock. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
  • 7/14/2017 – Glaukos Corp was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $45.00 price target on the stock. According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “

Glaukos Corp (GKOS) traded down 2.653% during mid-day trading on Tuesday, hitting $40.915. 226,134 shares of the stock were exchanged. The stock’s 50 day moving average is $38.49 and its 200 day moving average is $42.55. Glaukos Corp has a 52-week low of $28.72 and a 52-week high of $52.49. The stock’s market cap is $1.41 billion.

In other Glaukos Corp news, Director Orbimed Advisors Llc sold 325,000 shares of Glaukos Corp stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas William Burns sold 73,788 shares of Glaukos Corp stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 980,200 shares of company stock worth $37,900,263. Insiders own 16.40% of the company’s stock.

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Receive News & Stock Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related stocks with our FREE daily email newsletter.